021-51111890
购物车（0）
sales@molnova.cn
Isoescin IB
CAS No. 219944-46-4
Isoescin IB ( —— )
产品货号. M21793 CAS No. 219944-46-4
异七叶皂苷 IB（Isoescin IB）是从七叶树种子中分离出来的，是七叶皂苷 IB 的异构体。异七叶皂苷IB和七叶皂苷IB是七叶皂苷的主要活性成分。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥2268 | 有现货 |
|
| 10MG | ￥3362 | 有现货 |
|
| 25MG | ￥5573 | 有现货 |
|
| 100MG | 获取报价 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Isoescin IB
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述异七叶皂苷 IB（Isoescin IB）是从七叶树种子中分离出来的，是七叶皂苷 IB 的异构体。异七叶皂苷IB和七叶皂苷IB是七叶皂苷的主要活性成分。
-
产品描述Isoescin IB, isolated from horse chestnut tree seeds, is an isomer of Escin IB. Isoescin IB and Escin IB are the chief active ingredients in escin.
-
体外实验β-Escin (mainly consisting of escin Ia and escin Ib) is the major active ingredient in horse chestnut seeds extracts. β-escin can inhibit proliferation and/or induce apoptosis in various types of cancer cells including A549 cell, HT-29 cell, HCC cell, OVCAR3 cell and H-Ras 5RP7 cell. β-escin may be useful as a chemopreventive agent, especially for tumors associated with an inflammatory response. As the minor component of escin, α-escin (mainly consisting of isoescin Ia and isoescin Ib) exhibits lower bioactivity.
-
体内实验——
-
同义词——
-
通路Natural Products
-
靶点Terpenoids
-
受体——
-
研究领域——
-
适应症——
化学信息
-
CAS Number219944-46-4
-
分子量1131.26
-
分子式C??H??O??
-
纯度>98% (HPLC)
-
溶解度In Vitro:?DMSO : 100 mg/mL (88.40 mM)
-
SMILESCC(OC[C@]1([C@H]2O)[C@](CC(C)(C)[C@H]2OC(/C(C)=C\C)=O)([H])C3=CC[C@@]4([H])[C@@](C)(CC[C@]5([H])[C@@]4(CC[C@H](O[C@@](O[C@H](C(O)=O)[C@@H](O[C@]([C@@H]([C@@H](O)[C@@H]6O)O)([H])O[C@@H]6CO)[C@@H]7O)([H])[C@@H]7O[C@]([C@@H]([C@@H](O)[C@@H]8O)O)([H])O[C@@H]8CO)[C@]5(C)CO)C)[C@]3(C)C[C@H]1O)=O
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Wu XJ, et al. Comparative pharmacokinetics and the bioavailability of escin Ib and isoescin Ib following the administration of escin, pure escin Ib and isoescin Ib in rats.J Ethnopharmacol. 2014 Feb 3;151(2):839-45.
